Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Gliosarcoma × Basiliximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Hodgkin Disease 2 Glioblastoma 2 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hemoglobinuria, Paroxysmal 1 Gliosarcoma 1 Brain Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1 Anemia, Aplastic 1

Interventions

Temozolomide 87 Radiotherapy 63 Bevacizumab 33 Radiation 22 Carmustine 19 Erlotinib Hydrochloride 16 Irinotecan 15 Chemotherapy, Adjuvant 14 Magnetic Resonance Spectroscopy 12 O(6)-benzylguanine 10 sargramostim 9 Surgical Procedures, Operative 9 Radiotherapy, Conformal 9 Imatinib Mesylate 9 Radiotherapy, Intensity-Modulated 8 Carboplatin 8 motexafin gadolinium 7 Thalidomide 7 Gene Expression Profiling 7 Sirolimus 6 Radiosurgery 6 Immunohistochemistry 6 Hydroxyurea 6 Gefitinib 6 Everolimus 6 Cyclophosphamide 6 temsirolimus 5 cediranib 5 aldesleukin 5 Procarbazine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00626483 2021-03-09

REGULATe

Duke University

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡